menu
    • menu
    [{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-CVX1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"intranasal spray","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer\u2019s SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"NL-201","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NL-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NEO-TRA1","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Neurogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurogene and Neoleukin Announce Definitive Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Merger","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neoleukin Therapeutics \/ Neurogene","highestDevelopmentStatusID":"7","companyTruncated":"Neoleukin Therapeutics \/ Neurogene"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Neurogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Merger","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neoleukin Therapeutics \/ Neurogene","highestDevelopmentStatusID":"7","companyTruncated":"Neoleukin Therapeutics \/ Neurogene"}]

    Find Clinical Drug Pipeline Developments & Deals by Neoleukin Therapeutics

    Menu

    Neoleukin Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NGN-401

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Neurogene

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Mill...

                            Details : The combined company will focus on advancing Neurogene’s pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile.

                            Brand Name : NGN-401

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 19, 2023

                            Lead Product(s) : NGN-401

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Neurogene

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NGN-401

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Neurogene

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Neurogene and Neoleukin Announce Definitive Merger Agreement

                            Details : The combined company will focus on advancing Neurogene’s pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile.

                            Brand Name : NGN-401

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 18, 2023

                            Lead Product(s) : NGN-401

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Neurogene

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEO-TRA1

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Me...

                            Details : NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits that is targeted to and selectively expands inhibitory T-regulatory cells.

                            Brand Name : NEO-TRA1

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 12, 2022

                            Lead Product(s) : NEO-TRA1

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NL-201,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting

                            Details : NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.

                            Brand Name : NL-201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : NL-201,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NL-201,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 i...

                            Details : NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without any bias toward cells expressing the alpha receptor subunit (CD25).

                            Brand Name : NL-201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 16, 2022

                            Lead Product(s) : NL-201,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NL-201,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Ann...

                            Details : NL-201 is world’s first computationally designed de novo protein therapeutic, positioned as a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface for the trreatment of cancer...

                            Brand Name : NL-201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : NL-201,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NL-201

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

                            Details : The FDA has informed Neoleukin that it needs to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of...

                            Brand Name : NL-201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 08, 2021

                            Lead Product(s) : NL-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NL-201,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer...

                            Details : NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation.

                            Brand Name : NL-201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 10, 2020

                            Lead Product(s) : NL-201,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NL-CVX1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infectio...

                            Details : This report details the creation of de novo protein decoys that were specifically designed to bind the SARS-CoV-2 spike protein with high affinity, preventing its association with the viral receptor hACE2, which is required for infection.

                            Brand Name : CTC-445.2d

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 05, 2020

                            Lead Product(s) : NL-CVX1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Neoleukin Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NL-201

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the SITC 2020

                            Details : Poster titled "NL-201, a de novo IL-2/IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies" will be presented at the conference.

                            Brand Name : NL-201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 14, 2020

                            Lead Product(s) : NL-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth